A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
EXHALE-4
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
2 other identifiers
interventional
600
18 countries
335
Brief Summary
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Jan 2023
Typical duration for phase_3
335 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 30, 2023
CompletedFirst Submitted
Initial submission to the registry
February 20, 2023
CompletedFirst Posted
Study publicly available on registry
February 28, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedSeptember 5, 2025
August 1, 2025
2.6 years
February 20, 2023
August 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in pre-BD FEV₁ from baseline
Pre-bronchodilator forced expiratory volume (pre-BD) FEV₁, absolute change from baseline, averaged over Weeks 20 and 24.
Day 1 (baseline, pre-dose), Weeks 20, 24
Secondary Outcomes (7)
Change from baseline in Asthma Control Questionnaire-6 (ACQ-6)
Day 1 (baseline, pre-dose), Weeks 20, 24
Change in Standardized version of the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12) from baseline to Week 24.
Day 1 (baseline, pre-dose) through Week 24
Change from baseline absolute eosinophil count (AEC) averaged across Weeks 20 and 24.
Day 1 (baseline, pre-dose) through Week 24
Change from baseline forced vital capacity (FVC) averaged over Weeks 20 and 24.
Day 1 (baseline, pre-dose), Weeks 20, 24
Change from baseline forced vital capacity (FVC) at Weeks 4, 8, 12, 16, 20, and 24.
Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, and 24
- +2 more secondary outcomes
Study Arms (3)
150 mg BID
EXPERIMENTALDexpramipexole 150 mg oral tablet taken twice a day
75 mg BID
EXPERIMENTALDexpramipexole 75 mg oral tablet taken twice a day
Placebo
PLACEBO COMPARATORPlacebo oral tablet taken twice a day
Interventions
Eligibility Criteria
You may qualify if:
- Signed informed consent form and assent form, as appropriate.
- Male or female ≥12 years of age at Screening Visit 1. Sites in Poland will only include participants aged ≥18 years.
- Asthma-related criteria
- Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
- Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Note: In Poland, this will instead include participants requiring a minimum daily medium dose ICS (≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021). Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1.
- Pre-BD FEV1 ≥40% and \<80% (\<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2.
- ACQ-6 ≥1.5 at Screening Visit 2.
- Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2).
- General medical history
- Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits.
- WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit:
- A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive.
- Two protocol acceptable methods of contraception in tandem.
- Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply:
- Women \<50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range.
- +1 more criteria
You may not qualify if:
- Asthma-related criteria
- A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization prior to the Screening Visit 1 up to and including the Baseline Visit.
- Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.
- Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis).
- Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1.
- Prohibited medications/procedures
- Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long acting anti-interleukin-5) in the past 12 months.
- Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
- Treatment with pramipexole (Mirapex®) within 30 days of Baseline.
- Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1.
- Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the study period.
- General medical history
- Weight \<40 kg at Screening Visit 2.
- Current smoking within 12 months prior to Screening Visit 1 or a smoking history of \>10 packyears. Smoking includes tobacco, vaping, and/or marijuana use.
- Known or suspected alcohol or drug abuse.
- +22 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (335)
Research Site 40001-487
Chandler, Arizona, 85224, United States
Research Site 40001-462
Peoria, Arizona, 85381, United States
Research Site 40001-322
Surprise, Arizona, 85378, United States
Research Site 40001-374
Bakersfield, California, 93301, United States
Research Site 40001-227
Encinitas, California, 92024, United States
Research Site 40001-349
Huntington Beach, California, 92647, United States
Research Site 40001-485
Inglewood, California, 06410, United States
Research Site 40001-440
La Palma, California, 90623, United States
Research Site 40001-357
Lancaster, California, 93534, United States
Research Site 40001-089
Los Angeles, California, 90048, United States
Research Site 40001-362
Mission Viejo, California, 92691, United States
Research Site 40001-449
Napa, California, 94558, United States
Research Site 40001-062
Newport Beach, California, 92660, United States
Research Site 40001-043
Newport Beach, California, 92663, United States
Research Site 40001-380
Redding, California, 96001, United States
Research Site 40001-434
San Diego, California, 92123, United States
Research Site 40001-088
San Jose, California, 95117, United States
Research Site 40001-359
Upland, California, 91756, United States
Research Site 40001-003
West Covina, California, 91790, United States
Research Site 40001-419
Westminster, California, 92683, United States
Research Site 40001-425
Aurora, Colorado, 80014, United States
Research Site 40001-353
Colorado Springs, Colorado, 80907, United States
Research Site 40001-385
Wheat Ridge, Colorado, 80033, United States
Research Site 40001-048
Aventura, Florida, 33180, United States
Research Site 40001-005
Brandon, Florida, 33511, United States
Research Site 40001-051
Brandon, Florida, 33511, United States
Research Site 40001-029
Coral Gables, Florida, 33134, United States
Research Site 40001-350
Gainesville, Florida, 32607, United States
Research Site 40001-014
Greenacres City, Florida, 33467, United States
Research Site 40001-054
Hialeah, Florida, 33012, United States
Research Site 40001-067
Hialeah, Florida, 33016, United States
Research Site 40001-020
Homestead, Florida, 33030, United States
Research Site 40001-015
Kissimmee, Florida, 34744, United States
Research Site 40001-002
Kissimmee, Florida, 34746, United States
Research Site 40001-086
Loxahatchee Groves, Florida, 33470, United States
Research Site 40001-318
Maitland, Florida, 32751, United States
Research Site 40001-066
Miami, Florida, 33126, United States
Research Site 40001-001
Miami, Florida, 33135, United States
Research Site 40001-059
Miami, Florida, 33144, United States
Research Site 40001-026
Miami, Florida, 33155, United States
Research Site 40001-288
Miami, Florida, 33165, United States
Research Site 40001-065
Miami, Florida, 33173, United States
Research Site 40001-024
Miami, Florida, 33184, United States
Research Site 40001-338
Miami Beach, Florida, 33169, United States
Research Site 40001-348
Ocala, Florida, 34471, United States
Research Site 40001-293
Orlando, Florida, 32819, United States
Research Site 40001-429
Plantation, Florida, 33317, United States
Research Site 40001-351
Sarasota, Florida, 34239, United States
Research Site 40001-069
St. Petersburg, Florida, 33713, United States
Research Site 40001-370
Tallahassee, Florida, 32308, United States
Research Site 40001-004
Tampa, Florida, 33607, United States
Research Site 40001-319
Viera, Florida, 32940, United States
Research Site 40001-142
Adairsville, Georgia, 30103, United States
Research Site 40001-075
Augusta, Georgia, 30909, United States
Research Site 40001-018
Columbus, Georgia, 31904, United States
Research Site 40001-452
Dunwoody, Georgia, 30350, United States
Research Site 40001-483
East Point, Georgia, 30344, United States
Research Site 40001-366
Lilburn, Georgia, 30047, United States
Research Site 40001-423
Savannah, Georgia, 31406, United States
Research Site 40001-090
Berwyn, Illinois, 60402, United States
Research Site 40001-343
Chicago, Illinois, 60607, United States
Research Site 40001-358
Normal, Illinois, 61761, United States
Research Site 40001-135
River Forest, Illinois, 60305, United States
Research Site 40001-403
Skokie, Illinois, 60077, United States
Research Site 40001-036
Elwood, Indiana, 46036, United States
Research Site 40001-347
Louisville, Kentucky, 40202, United States
Research Site 40001-019
Owensboro, Kentucky, 42301, United States
Research Site 40001-437
Alexandria, Louisiana, 71303, United States
Research Site 40001-313
Marrero, Louisiana, 70072, United States
Research Site 40001-352
Zachary, Louisiana, 70791, United States
Research Site 40001-417
Annapolis, Maryland, 21401, United States
Research Site 40001-466
Baltimore, Maryland, 21237, United States
Research Site 40001-456
Takoma Park, Maryland, 20912, United States
Research Site 40001-055
White Marsh, Maryland, 21162, United States
Research Site 40001-468
Fall River, Massachusetts, 02723, United States
Research Site 40001-427
Dearborn, Michigan, 48126, United States
Research Site 40001-006
Flint, Michigan, 48504, United States
Research Site 40001-148
Flint, Michigan, 48507, United States
Research Site 40001-463
Rochester Hills, Michigan, 48307, United States
Research Site 40001-442
Southfield, Michigan, 48034, United States
Research Site 40001-372
Warren, Michigan, 48088, United States
Research Site 40001-421
Mankato, Minnesota, 56001, United States
Research Site 40001-083
Columbia, Missouri, 65203, United States
Research Site 40001-074
Saint Charles, Missouri, 63301, United States
Research Site 40001-046
St Louis, Missouri, 63110, United States
Research Site 40001-409
Missoula, Montana, 59808, United States
Research Site 40001-448
Lincoln, Nebraska, 68510, United States
Research Site 40001-404
Omaha, Nebraska, 68798, United States
Research Site 40001-473
Las Vegas, Nevada, 89109, United States
Research Site 40001-387
Brick, New Jersey, 08724, United States
Research Site 40001-363
Edison, New Jersey, 08817, United States
Research Site 40001-457
Jersey City, New Jersey, 07304, United States
Research Site 40001-355
Toms River, New Jersey, 08755, United States
Research Site 40001-050
East Amherst, New York, 14051, United States
Research Site 40001-412
Great Neck, New York, 11021, United States
Research Site 40001-047
Hawthorne, New York, 10532, United States
Research Site 40001-455
New York, New York, 10016, United States
Research Site 40001-369
New York, New York, 10029, United States
Research Site 40001-408
Charlotte, North Carolina, 28273, United States
Research Site 40001-398
Charlotte, North Carolina, 28277, United States
Research Site 40001-039
Gastonia, North Carolina, 28054, United States
Research Site 40001-435
Greenville, North Carolina, 17834, United States
Research Site 40001-111
Huntersville, North Carolina, 28078, United States
Research Site 40001-382
Raleigh, North Carolina, 27610, United States
Research Site 40001-439
Rocky Mount, North Carolina, 27804, United States
Research Site 40001-283
Winston-Salem, North Carolina, 21704, United States
Research Site 40001-034
Cincinnati, Ohio, 45215, United States
Research Site 40001-013
Cincinnati, Ohio, 45219, United States
Research Site 40001-010
Cincinnati, Ohio, 45236, United States
Research Site 40001-413
Cleveland, Ohio, 44106, United States
Research Site 40001-017
Dayton, Ohio, 45424, United States
Research Site 40001-063
Toledo, Ohio, 43617, United States
Research Site US-40001-038
Edmond, Oklahoma, 73034, United States
Research Site 40001-386
Oklahoma City, Oklahoma, 73102, United States
Research Site 40001-079
Oklahoma City, Oklahoma, 73120, United States
Research Site 40001-027
Grants Pass, Oregon, 97527, United States
Research Site 40001-337
Portland, Oregon, 97202, United States
Research Site 40001-395
Hershey, Pennsylvania, 17033, United States
Research Site 40001-327
Philadelphia, Pennsylvania, 19140, United States
Research Site 40001-032
Columbia, South Carolina, 29204, United States
Research Site 40001-025
Greenville, South Carolina, 29651, United States
Research Site 40001-430
Rock Hill, South Carolina, 29732, United States
Research Site 40001-073
Spartanburg, South Carolina, 29303, United States
Research Site 40001-438
Dickson, Tennessee, 37055, United States
Research Site 40001-414
Franklin, Tennessee, 37067, United States
Research Site 40001-334
Allen, Texas, 75013, United States
Research Site 40001-068
Amarillo, Texas, 79124, United States
Research Site 40001-023
Dallas, Texas, 75230, United States
Research Site 40001-028
Dallas, Texas, 75235, United States
Research Site 40001-415
Dallas, Texas, 75246, United States
Research Site 40001-304
DeSoto, Texas, 75115, United States
Research Site 40001-418
Frisco, Texas, 75034, United States
Research Site 40001-064
Houston, Texas, 77074, United States
Research Site 40001-085
Houston, Texas, 77099, United States
Research Site 40001-424
Kerrville, Texas, 78028, United States
Research Site 40001-295
McKinney, Texas, 75069, United States
Research Site 40001-304
Red Oak, Texas, 75154, United States
Research Site 40001-377
San Antonio, Texas, 78258, United States
Research Site 40001-335
Sugar Land, Texas, 77479, United States
Research Site 40001-258
Murray, Utah, 84107, United States
Research Site 40001-333
Pleasant View, Utah, 84404, United States
Research Site 40001-340
Burke, Virginia, 22015, United States
Research Site 40001-394
Williamsburg, Virginia, 23188, United States
Research Site 40001-339
Greenfield, Wisconsin, 53228, United States
Research Site 40001-433
La Crosse, Wisconsin, 54601, United States
Research Site 40001-443
La Crosse, Wisconsin, 54601, United States
Research Site 40054-035
Buenos Aires, B1878FNR, Argentina
Research Site 40054-044
Buenos Aires, B1878FNR, Argentina
Research Site 40054-034
Buenos Aires, B8000JRB, Argentina
Research Site 40054-017
Buenos Aires, C1027AAP, Argentina
Research Site 40054-008
Buenos Aires, C1426ABP, Argentina
Research Site 40054-043
Buenos Aires, C14426ABP, Argentina
Research Site 40054-015
Caba, C1121ABE, Argentina
Research Site 40054-019
Mendoza, M5500AXR, Argentina
Research Site 40054-016
Mendoza, M5500CBA, Argentina
Research Site 40054-010
Mendoza, M5500CCG, Argentina
Research Site 40054-028
Mendoza, M5501AAJ, Argentina
Research Site 40054-032
Mendoza, M5501GCA, Argentina
Research Site 40054-057
Mendoza, M5506BBH, Argentina
Research Site 40054-024
San Miguel de Tucumán, C1425BEN, Argentina
Research Site 40054-002
San Miguel de Tucumán, T4000CBC, Argentina
Research Site 40054-020
San Miguel de Tucumán, T4000IAJ, Argentina
Research Site 30043-013
Salzburg, 5020, Austria
Research Site 40055-015
Belo Horizonte, Brazil
Research Site 40055-007
Blumenau, 89030-101, Brazil
Research Site 40055-011
Campo Largo, 83606-177, Brazil
Research Site 40055-043
Curitiba, 80060-900, Brazil
Research Site 40055-036
Curitiba, 80810-100, Brazil
Research Site 40055-012
Porto Alegre, 90035-074, Brazil
Research Site 40055-004
Porto Alegre, 90610-000, Brazil
Research Site 40055-010
Porto Alegre, 91010-006, Brazil
Research Site 40055-035
Rio de Janeiro, 22061-080, Brazil
Research Site 40055-025
Salvador, 40060-325, Brazil
Research Site 40055-005
Santo André, 09060-870, Brazil
Research Site 40055-009
Santos, 11075-900, Brazil
Research Site 40055-001
São Bernardo do Campo, 09715-090, Brazil
Research Site 40011-004
Ajax, Ontario, L1S 2J5, Canada
Research Site 40011-016
Ajax, Ontario, L1Z 0M1, Canada
Research Site 40011-010
Burlington, Ontario, L7N, Canada
Research Site 40011-014
Ottawa, Ontario, K1H 1E4, Canada
Research Site 40011-005
Windsor, Ontario, N8X 2G1, Canada
Research Site 40011-001
Windsor, Ontario, N8X 5A6, Canada
Research Site 40011-018
Montreal, Quebec, H4A 3J1, Canada
Research Site 40011-022
Québec, Quebec, G1G 3Y8, Canada
Research Site 40011-020
Trois-Rivières, Quebec, G9A 4P3, Canada
Research Site 40011-011
Vancouver, V5Z 1M9, Canada
Research Site 40972-010
Ashkelon, 7830604, Israel
Research Site 40972-008
Beersheba, 8410101, Israel
Research Site 40972-005
Haifa, 3109601, Israel
Research Site 40972-004
Haifa, 3436212, Israel
Research Site 40972-001
Jerusalem, Israel
Research Site 40972-009
Kfar Saba, 4428164, Israel
Research Site 40972-002
Petah Tikva, 4941492, Israel
Research Site 40972-011
Ramat Gan, 5262000, Israel
Research Site 30060-006
Kampung Kelantan, Malaysia
Research Site 40052-026
Chihuahua City, 31203, Mexico
Research Site 40052-007
Guadalajara, 044100, Mexico
Research Site 40052-028
Mexico City, 06700, Mexico
Research Site 40052-012
San Juan del Río, 76800, Mexico
Research Site 40048-001
Będzin, 42-500, Poland
Research Site 40048-018
Bialystok, 15-044, Poland
Research Site 40048-032
Bialystok, 15-430, Poland
Research Site 40048-023
Gdansk, 80-214, Poland
Research Site 40048-006
Giżycko, 11-500, Poland
Research Site 40048-021
Katowice, 40-081, Poland
Research Site 40048-002
Katowice, 40-365, Poland
Research Site 40048-027
Krakow, 30-033, Poland
Research Site 40048-033
Krakow, 31-011, Poland
Research Site 40048-008
Krakow, 31-159, Poland
Research Site 40048-040
Krakow, 31-864, Poland
Research Site 40048-015
Lodz, 90-141, Poland
Research Site 40048-009
Lodz, 90-302, Poland
Research Site 40048-005
Lodz, 90-549, Poland
Research Site 40048-022
Lublin, 20-089, Poland
Research Site 40048-024
Maków Podhalański, 34-220, Poland
Research Site 40048-031
Ostrowiec Świętokrzyski, 27-400, Poland
Research Site 40048-010
Piaseczno, 05-500, Poland
Research Site 40048-016
Poznan, 61-578, Poland
Research Site 40048-039
Rzeszów, 35-205, Poland
Research Site 40048-014
Skierniewice, 96-100, Poland
Research Site 40048-012
Trzebnica, 55-100, Poland
Research Site 40048-019
Wroclaw, 51-162, Poland
Research Site 40787-365
Guaynabo, 00968, Puerto Rico
Research Site 40787-390
Ponce, 00717, Puerto Rico
Research Site 40787-388
San Juan, 00907, Puerto Rico
Research Site 40787-383
San Juan, 00918, Puerto Rico
Research Site 40787-405
San Juan, 00918, Puerto Rico
Research Site 40787-360
San Juan, 00927, Puerto Rico
Research Site 40787-345
Vega Baja, 00694, Puerto Rico
Research Site 40040-004
Brasov, Brașov County, 50366, Romania
Research Site 40040-006
Cluj-Napoca, Cluj, 400371, Romania
Research Site 40040-002
Brasov, 500051, Romania
Research Site 40040-009
Cluj-Napoca, 400162, Romania
Research Site 40040-007
Cluj-Napoca, 400371, Romania
Research Site 40040-001
Constanța, 900002, Romania
Research Site 40040-010
Sângeorgiu de Mureş, 547365, Romania
Research Site 40040-003
Timișoara, 300310, Romania
Research Site 40027-013
Benoni, 1500, South Africa
Research Site 40027-025
Cape Town, 7505, South Africa
Research Site 40027-009
Cape Town, 7530, South Africa
Research Site 40027-011
Cape Town, 7570, South Africa
Research Site 40027-021
Cape Town, 7700, South Africa
Research Site 30090-020
Durban, 4001, South Africa
Research Site 40027-007
Durban, 7570, South Africa
Research Site 40027-026
Johannesburg, 2193, South Africa
Research Site 40027-005
KwaZulu, 4001, South Africa
Research Site 40027-008
KwaZulu, 4092, South Africa
Research Site 40027-020
KwaZulu, 4170, South Africa
Research Site 40027-023
KwaZulu, 4301, South Africa
Research Site 40027-027
KwaZulu, 4301, South Africa
Research Site 40027-010
KwaZulu, 4450, South Africa
Research Site 40027-006
Mpumalanga, 1050, South Africa
Research Site 40027-004
Pretoria, 0002, South Africa
Research Site 40027-019
Pretoria, 0204, South Africa
Research Site 40027-018
Vereeniging, 1935, South Africa
Research Site 40027-017
Welkom, 9460, South Africa
Research Site 40082-003
Anyang-si, 14068, South Korea
Research Site 30082-024
Bucheon-si, 14584, South Korea
Research Site 40082-007
Busan, 48108, South Korea
Research Site 40082-021
Gwangju, 61469, South Korea
Research Site 40082-020
Incheon, 21565, South Korea
Research Site 40082-006
Jeonju, 54907, South Korea
Research Site 40082-019
Seoul, 04763, South Korea
Research Site 40082-012
Seoul, 05030, South Korea
Research Site 40082-008
Seoul, 06591, South Korea
Research Site 40082-004
Seoul, 07061, South Korea
Research Site 40082-011
Seoul, 08308, South Korea
Research Site 40082-010
Suwon, 16499, South Korea
Research Site 40886-001
Kaohsiung City, 807, Taiwan
Research Site 40886-004
New Taipei City, 220, Taiwan
Research Site 40886-006
New Taipei City, 23561, Taiwan
Research Site 40886-005
Taichung, 40403, Taiwan
Research Site 40886-007
Taichung, 40705, Taiwan
Research Site 40886-010
Taipei, 100, Taiwan
Research Site 40886-008
Taipei, 110, Taiwan
Research Site 40866-003
Taipei, 11217, Taiwan
Research Site 40886-009
Taipei, 11240, Taiwan
Research Site 30066-004
Pathum Thani, 12120, Thailand
Research Site 40090-002
Adana, 01240, Turkey (Türkiye)
Research Site 40090-018
Ankara, 06230, Turkey (Türkiye)
Research Site 40090-021
Ankara, 06230, Turkey (Türkiye)
Research Site 40090-024
Ankara, 06230, Turkey (Türkiye)
Research Site 40090-003
Ankara, 06560, Turkey (Türkiye)
Research Site 40090-025
Ankara, 06560, Turkey (Türkiye)
Research Site 40090-008
Ankara, 06620, Turkey (Türkiye)
Research Site 40090-009
Ankara, 06930, Turkey (Türkiye)
Research Site 40090-017
Antalya, 07400, Turkey (Türkiye)
Research Site 40090-019
Bornova, 35100, Turkey (Türkiye)
Research Site 40090-020
Istanbul, 34020, Turkey (Türkiye)
Research Site 40090-026
Istanbul, 34750, Turkey (Türkiye)
Research Site 40090-011
Istanbul, 34844, Turkey (Türkiye)
Research Site 40090-012
Konak, 35110, Turkey (Türkiye)
Research Site 40090-016
Merkez, 17020, Turkey (Türkiye)
Research Site 40090-013
Mersin, 33110, Turkey (Türkiye)
Research Site 40090-024
Pendik, Turkey (Türkiye)
Research Site 40090-022
Tekirdağ, 59100, Turkey (Türkiye)
Research Site 40380-002
Chernivtsi, 58001, Ukraine
Research Site 40380-021
Chernivtsi, 58022, Ukraine
Research Site 40380-009
Ivano-Frankivsk, 76008, Ukraine
Research Site 40380-004
Ivano-Frankivsk, 76018, Ukraine
Research Site 40380-017
Ivano-Frankivsk, 76018, Ukraine
Research Site 40380-014
Ivano-Frankivsk, 76019, Ukraine
Research Site 40380-019
Kyiv, 02002, Ukraine
Research Site 40380-018
Kyiv, 03037, Ukraine
Research Site 40380-007
Kyiv, 03038, Ukraine
Research Site 40380-010
Kyiv, 03038, Ukraine
Research Site 40380-012
Kyiv, 03038, Ukraine
Research Site 40380-015
Kyiv, 03049, Ukraine
Research Site 40380-011
Kyiv, 03057, Ukraine
Research Site 40380-013
Kyiv, 03115, Ukraine
Research Site 40380-016
Lutsk, 45634, Ukraine
Research Site 40380-001
Ternopil, 46023, Ukraine
Research Site 40380-003
Vinnytsia, 21001, Ukraine
Research Site 40380-020
Vinnytsia, 21018, Ukraine
Research Site 40380-008
Vinnytsia, 21029, Ukraine
Research Site 40380-022
Vinnytsia, 21029, Ukraine
Research Site 40380-005
Zhytomyr, 10002, Ukraine
Research Site 40044-018
Bellshill, ML4 3NJ, United Kingdom
Research Site 40044-021
Birmingham, B15 2SQ, United Kingdom
Research Site 40044-077
Bollington, SK10 5JH, United Kingdom
Research Site 40044-017
Chorley, PR7 7NA, United Kingdom
Research Site 40044-022
Enfield, EN3 4GS, United Kingdom
Research Site 40044-019
Liverpool, L22 0LG, United Kingdom
Research Site 40044-084
London, E1 1 EQ, United Kingdom
Research Site 40044-001
Manchester, BL9 0NJ, United Kingdom
Research Site 40044-020
Manchester, M15 6SE, United Kingdom
Research Site 40044-013
Manchester, M22 4DH, United Kingdom
Research Site 40044-009
Manchester, M24 4DZ, United Kingdom
Research Site 40044-036
Manchester, M27 0EW, United Kingdom
Research Site 40044-006
Manchester, M33 4BR, United Kingdom
Research Site 40044-024
Preston, PR2 9RB, United Kingdom
Research Site 40044-026
Rochdale, OL11 4AU, United Kingdom
Research Site 40044-008
Salford, M6 5WW, United Kingdom
Research Site 40044-034
Stockport, SK8 5LL, United Kingdom
Research Site 40044-078
Wythenshawe, M23 9QZ, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mona Bafadhel, MD
Guy's and St Thomas' NHS Foundation Trust
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 20, 2023
First Posted
February 28, 2023
Study Start
January 30, 2023
Primary Completion
September 1, 2025
Study Completion
December 1, 2025
Last Updated
September 5, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share